CLEC9A and neoplasm: The priming of the immune response is a mechanism in which initially DNGR-1+ dendritic cells (first characterised in mice as CD8α+ dendritic cells) acquire antigens from dying tumour cells and target the antigens for cross-presentation via the class I major histocompatibility complex (MHC) processing pathway [61,62].